Greenland Mines Announces Canadian Patent for Klotho Gene Therapy Technology
Key Takeaways
- •Canada granted Greenland Mines a patent covering exclusively licensed Klotho-based gene therapy technology.
- •The patent includes 42 claims tied to the secreted Klotho RNA splice variant and its use in multiple neurodegenerative diseases.
- •Greenland Mines said the new patent complements previously issued patents in the United States, China and Europe.
- •KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
- •Process development and manufacturing for KLTO-101 is scheduled to begin in August 2026.
Greenland Mines Ltd. (NASDAQ: GRML) said Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The patent grant adds another jurisdiction to a patent set the company says is intended to support its biotech division as it develops Klotho gene therapy programs.
Greenland Mines is a Nasdaq-listed company with two operating divisions: mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland; and biotech, including Klotho’s KLTO-202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The Canadian patent is expected to strengthen Greenland Mines’ intellectual property protection for its Klotho-based therapeutics, which are being developed to address significant unmet medical needs in neurodegenerative diseases. The company said KLTO-202 has advanced to GMP manufacturing, indicating progress toward potential clinical trials. For more details, the full press release is available at